Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q34529311)
Watch
English
Idelalisib in the management of lymphoma.
scientific article
In more languages
default for all languages
No label defined
No description defined
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PMC publication ID
5161010
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27252232%20AND%20SRC:MED&resulttype=core&format=json
retrieved
3 April 2020
review article
1 reference
stated in
Europe PubMed Central
title
Idelalisib in the management of lymphoma
(English)
1 reference
stated in
Europe PubMed Central
PMC publication ID
5161010
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27252232%20AND%20SRC:MED&resulttype=core&format=json
retrieved
3 April 2020
author
Chan Yoon Cheah
series ordinal
1
1 reference
stated in
Europe PubMed Central
PMC publication ID
5161010
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27252232%20AND%20SRC:MED&resulttype=core&format=json
retrieved
3 April 2020
author name string
Nathan H Fowler
series ordinal
2
1 reference
stated in
Europe PubMed Central
PMC publication ID
5161010
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27252232%20AND%20SRC:MED&resulttype=core&format=json
retrieved
3 April 2020
language of work or name
English
0 references
publication date
1 June 2016
1 reference
stated in
Europe PubMed Central
PMC publication ID
5161010
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27252232%20AND%20SRC:MED&resulttype=core&format=json
retrieved
3 April 2020
published in
Blood
1 reference
stated in
Europe PubMed Central
PMC publication ID
5161010
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27252232%20AND%20SRC:MED&resulttype=core&format=json
retrieved
3 April 2020
volume
128
1 reference
stated in
Europe PubMed Central
PMC publication ID
5161010
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27252232%20AND%20SRC:MED&resulttype=core&format=json
retrieved
3 April 2020
issue
3
1 reference
stated in
Europe PubMed Central
PMC publication ID
5161010
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27252232%20AND%20SRC:MED&resulttype=core&format=json
retrieved
3 April 2020
page(s)
331-336
1 reference
stated in
Europe PubMed Central
PMC publication ID
5161010
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27252232%20AND%20SRC:MED&resulttype=core&format=json
retrieved
3 April 2020
cites work
Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5161010
retrieved
7 July 2018
Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5161010
retrieved
7 July 2018
Idelalisib-associated Enterocolitis: Clinicopathologic Features and Distinction From Other Enterocolitides
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5161010
retrieved
7 July 2018
Clinical Pharmacokinetic and Pharmacodynamic Profile of Idelalisib
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5161010
retrieved
7 July 2018
Idelalisib: A Novel PI3Kδ Inhibitor for Chronic Lymphocytic Leukemia
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5161010
retrieved
7 July 2018
Targeted therapies in CLL: mechanisms of resistance and strategies for management
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5161010
retrieved
7 July 2018
Targeting neoplastic B cells and harnessing microenvironment: the "double face" of ibrutinib and idelalisib
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5161010
retrieved
7 July 2018
Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5161010
retrieved
7 July 2018
Infections associated with bendamustine containing regimens in hematological patients: a retrospective multi-center study
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5161010
retrieved
7 July 2018
MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K/AKT pathway in diffuse large B-cell lymphoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5161010
retrieved
7 July 2018
Management of adverse events associated with idelalisib treatment: expert panel opinion
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5161010
retrieved
7 July 2018
Constitutive AKT activation in follicular lymphoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5161010
retrieved
7 July 2018
A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL).
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5161010
retrieved
7 July 2018
Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5161010
retrieved
7 July 2018
PI3K and cancer: lessons, challenges and opportunities
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5161010
retrieved
7 July 2018
PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5161010
retrieved
7 July 2018
Idelalisib and rituximab in relapsed chronic lymphocytic leukemia
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5161010
retrieved
7 July 2018
PI3K-δ and PI3K-γ inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5161010
retrieved
7 July 2018
P110α-mediated constitutive PI3K signaling limits the efficacy of p110δ-selective inhibition in mantle cell lymphoma, particularly with multiple relapse
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5161010
retrieved
7 July 2018
Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5161010
retrieved
7 July 2018
PI3Kδ inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5161010
retrieved
7 July 2018
The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5161010
retrieved
7 July 2018
CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5161010
retrieved
7 July 2018
Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5161010
retrieved
7 July 2018
The PI3K pathway as drug target in human cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5161010
retrieved
7 July 2018
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5161010
retrieved
7 July 2018
Phosphatidylinositol 3'-kinase catalytic subunit alpha gene amplification contributes to the pathogenesis of mantle cell lymphoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5161010
retrieved
7 July 2018
Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5161010
retrieved
7 July 2018
Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5161010
retrieved
7 July 2018
Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5161010
retrieved
7 July 2018
Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5161010
retrieved
7 July 2018
Idelalisib-related pneumonitis.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5161010
retrieved
27 October 2018
Premature closure of a phase II study of bendamustine, mitoxantrone and rituximab for patients with untreated high-risk follicular lymphoma due to severe haematological and infectious toxicity
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5161010
retrieved
27 October 2018
Idelalisib-associated Colitis: Histologic Findings in 14 Patients.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5161010
retrieved
27 October 2018
Cytomegalovirus reactivation with bendamustine in patients with low-grade B-cell lymphoma.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5161010
retrieved
27 October 2018
PI3K signalling: the path to discovery and understanding.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5161010
retrieved
27 October 2018
Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5161010
retrieved
27 October 2018
Identifiers
DOI
10.1182/BLOOD-2016-02-702761
1 reference
stated in
Europe PubMed Central
PMC publication ID
5161010
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27252232%20AND%20SRC:MED&resulttype=core&format=json
retrieved
3 April 2020
PMC publication ID
5161010
1 reference
stated in
Europe PubMed Central
PMC publication ID
5161010
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27252232%20AND%20SRC:MED&resulttype=core&format=json
retrieved
3 April 2020
PubMed publication ID
27252232
1 reference
stated in
Europe PubMed Central
PMC publication ID
5161010
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27252232%20AND%20SRC:MED&resulttype=core&format=json
retrieved
3 April 2020
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit
